0000000000065804

AUTHOR

Giangennaro Coppola

0000-0002-9574-0081

showing 13 related works from this author

Impact of COVID-19 Pandemic on Children and Adolescents with Neuropsychiatric Disorders: Emotional/Behavioral Symptoms and Parental Stress.

2022

The objective of our study was to evaluate the impact of the COVID-19 pandemic on the emotional and behavioral symptoms in minors with neuropsychiatric disorders and on parental stress through a standardized neuropsychological assessment, comparing the data collected before the pandemic with those collected during the lock-down. Another goal of our study was to analyze the relationship between parental stress and behavioral/emotional symptoms in children. Our study was conducted on 383 families of patients who had already been referred at the Child Neuropsychiatry Unit of the University Hospital of Salerno for different neuropsychiatric conditions. All the parents completed two neuropsychol…

COVID-19; neuropsychiatric disorders; children; adolescents; emotional behavioral symptoms; parental stressProblem BehaviorPandemicAdolescentParentingHealth Toxicology and MutagenesisPublic Health Environmental and Occupational HealthCOVID-19parental stressNeuropsychiatric disorderParental streCommunicable Disease ControlHumansChildChildrenPandemicsEmotional behavioral symptomHumanInternational journal of environmental research and public health
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Familial Hemiplegic Migraine with an ATP1A4 Mutation: Clinical Spectrum and Carbamazepine Efficacy

2020

An Italian family with familial hemiplegic migraine (FHM) with the absence of mutations in the known genes associated with this disorder, namely ATP1A2, ATP1A3, CACNA1A, and SCN1A, has recently been reported. Soon afterward, whole exome sequencing allowed the identification of the carrier status of a heterozygous ATP1A4 mutation c.1798 C >T, in four affected members of this family. Here we compare the clinical symptoms of the affected family members with those from the other FHM families linked to mutations in the known genes associated with this disorder. A further two-year follow-up, including clinical response to carbamazepine administered to the proband and the maternal grandmother due …

ProbandPediatricsmedicine.medical_specialtyATP1A4 genefamilial hemiplegic migraine; ATP1A4 gene; carbamazepine; clinical symptomsCase Reportmedicine.disease_causelcsh:RC321-57103 medical and health sciences0302 clinical medicineATP1A2ATP1A3medicine<i>ATP1A4</i> genefamilial hemiplegic migrainelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryExome sequencingFamilial hemiplegic migraine030304 developmental biologyclinical symptoms0303 health sciencesMutationbusiness.industryGeneral NeuroscienceCarbamazepinemedicine.diseaseMigrainecarbamazepinebusiness030217 neurology & neurosurgerymedicine.drugBrain Sciences
researchProduct

Digital Devices Use and Language Skills in Children between 8 and 36 Month

2020

Background: Over the past decade, the use of digital tools has grown and research evidence suggests that traditional media and new media offer both benefits and health risks for young children. The abilities to understand and use language represent two of the most important competencies developed during the first 3 years of life through the interaction of the child with people, objects, events, and other environmental factors. The main goal of our study is to evaluate the relationship between digital devices use and language abilities in children between 8 and 36 month, also considering the influence of several factors. Materials and Methods: We conducted a cross-sectional observational stu…

educationAffect (psychology)Articlelcsh:RC321-571digital devicesDigital mediaDevelopmental psychologydigital devices; digital media; toddler; children; language abilities03 medical and health sciences0302 clinical medicinechildren030225 pediatrics0501 psychology and cognitive sciencesToddlerlcsh:Neurosciences. Biological psychiatry. Neuropsychiatrydigital medialanguage abilitiesbusiness.industryGeneral Neuroscience05 social sciencesRegression analysistoddlerModerationSocial relationObservational studybusinessPsychology050104 developmental & child psychologyGestureBrain Sciences
researchProduct

Hyperekplexia caused by dominant-negative suppression of glyra1 function.

2007

Hyperekplexia (HE; startle disease; OMIM#149400) is a rare inheritable neurologic disorder characterized by an exaggerated response to sudden stimuli, muscular rigidity, and hyperreflexia, leading to chronic injuries due to unprotected falls. All symptoms are present at birth but gradually decline during the first year of life, although an exaggerated startle response remains during adulthood.1 Dysfunctional inhibitory neurotransmission by glycine (Gly) plays a central role in HE pathogenesis. All patients with HE carry mutations in genes encoding either for α1 (GLYRA1) or β (GLYRB) Gly receptor subunits, presynaptic Gly transporters (SLC6A5), or proteins involved in Gly receptor (GLYR) clu…

Malemedicine.medical_specialtySubunitReflex StartleNonsense mutationCompound heterozygosityGeneReceptors GlycineInternal medicinemedicineMissense mutationHumansGlycine ReceptorHyperekplexiaGlycine receptorNervous System DiseaseGeneticsStartle DiseaseNeuroscience (all)GephyrinbiologyInfantPenetrancePedigreeEndocrinologyHyperekplexiaNON PREVISTO DA NORME REDAZIONALI (“NEUROLOGY”)Codon NonsenseMutationbiology.proteinNeurology (clinical)medicine.symptomNervous System DiseasesCollybistinHuman
researchProduct

Psychogenic nonepileptic seizures in pediatric population: A review

2019

Abstract Introduction Psychogenic nonepileptic seizures (PNES) are observable abrupt paroxysmal changes in behavior or consciousness that resemble epileptic seizures, but without concurrent electroencephalographic abnormalities. Methods In this manuscript, we reviewed literature concerning pediatric PNES and focused on those articles published in the last 10 years, in order to try to understand what the state of the art is at the moment, particularly as regards relationship and differential diagnosis with epilepsy. Results Psychogenic nonepileptic seizures have been extensively described in literature mainly in adults and less frequently in children. Despite the potential negative impact of…

MalePediatricsmedicine.medical_specialtyVideo eegAdolescentConsciousnessReviewsReview050105 experimental psychologylcsh:RC321-571Diagnosis Differential03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicinechildrenSeizureschildren psychogenic seizures video EEGvideo EEGPsychogenic diseaseMedicineHumans0501 psychology and cognitive sciencespsychogenic seizureChildSomatoform DisordersPathologicallcsh:Neurosciences. Biological psychiatry. NeuropsychiatryEpilepsychildren; psychogenic seizures; video EEGbusiness.industry05 social sciencesElectroencephalographymedicine.diseasePsychogenic Seizurepsychogenic seizuresFemaleDifferential diagnosisbusiness030217 neurology & neurosurgeryPediatric population
researchProduct

The predictive role of C-reactive protein in patients with hypertension and subclinical atherosclerosis.

2009

Recent guidelines published by the joint European Society of Hypertension/European Society of Cardiology have suggested the inclusion of C-reactive protein (CRP) in the standard assessment of cardiovascular risk in hypertensive patients, but little data is available on the role of CRP in patients with carotid lesions. We studied in 472 subjects, 236 with and 236 without hypertension, gender- and age-matched, with and without early stages of atherosclerosis (e.g. those with asymptomatic intima-media thickness >0.9 mm), the influence of all the other traditional cardiovascular risk factors (e.g. older age, male gender, obesity, diabetes, smoking habit, family history of coronary artery diseas…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaInflammationAsymptomaticCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineDiabetes mellitusCRP Hypertension Subclinical Atherosclerosis atherosclerosisInternal MedicinemedicineHumansIn patientFamily historyAgedbiologybusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseC-reactive protein hypertension inflammation event atherosclerosisAtherosclerosisObesitySettore MED/11 - Malattie Dell'Apparato CardiovascolareCerebrovascular DisordersC-Reactive ProteinCase-Control StudiesHypertensionCardiologybiology.proteinFemalemedicine.symptombusinessBiomarkersFollow-Up StudiesInternal medicine journal
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct

Social Cognition in Neurodevelopmental Disorders and Epilepsy

2021

Introduction: The purpose of our study was to perform a comparative analysis of social cognition in children and adolescents with epilepsy, autism spectrum disorder (ASD), specific learning disorder (SLD) and in typical development (TD) controls. The secondary aim was to relate social cognition to some clinical and demographic characteristics.Methods: Our work is a transversal observational study. The recruits were 179 children and adolescents aged between 6 and 18 years diagnosed with epilepsy, ASD, or SLD and 32 subjects with TD. All the participants underwent neuropsychological assessment of Emotion Recognition (ER) and Theory of Mind (ToM) skills.Results: All three clinical groups perfo…

genetic structuresautism spectrum disordersocial cognitionbehavioral disciplines and activitieslcsh:RC346-429EpilepsychildrenSocial cognitionTheory of mindmedicineSpecific Learning DisorderNeuropsychological assessmentEmotion recognitionautism spectrum disorder children epilepsy social cognition specific learning disorderlcsh:Neurology. Diseases of the nervous systemOriginal Researchmedicine.diagnostic_testspecific learning disordermedicine.diseaseSettore MED/39 - Neuropsichiatria InfantileNeurologyAutism spectrum disorderepilepsyObservational studyNeurology (clinical)PsychologyClinical psychologyFrontiers in Neurology
researchProduct

Facial emotion recognition in children and adolescents with specific learning disorder

2020

(1) Background: Some recent studies suggest that children and adolescents with different neurodevelopmental disorders perform worse in emotions recognition through facial expressions (ER) compared with typically developing peers. This impairment is also described in children with Specific Learning Disorders (SLD), compromising their scholastic achievement, social functioning, and quality of life. The purpose of our study is to evaluate ER skills in children and adolescents with SLD compared to a control group without learning disorders, and correlate them with intelligence and executive functions. (2) Materials and Methods: Our work is a cross-sectional observational study. Sixty-three chil…

Adolescentmedia_common.quotation_subjectAngerArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicineExecutive functionSpecific Learning DisorderadolescentsFacial emotion recognitionlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryChildrenmedia_commonFacial expressionIntelligence quotientWorking memoryGeneral NeuroscienceNeuropsychologyExecutive functionsexecutive functions030227 psychiatryfacial emotion recognition; specific learning disorder; children; adolescents; executive functionsSpecific learning disorderObservational studyPsychology030217 neurology & neurosurgeryClinical psychology
researchProduct

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome

2011

Background:&#8194; To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Methods:&#8194; Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7&#8195;±&#8195;8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4&#8195;months (range 3-26&#8195;months). Results:&#8194; Fifteen of 38 patients (39.5%) had a &#8805;50% seizure reduction in co…

AdultMalePediatricsmedicine.medical_specialtyAdolescentrufinamideRufinamideIrritabilityrefractory seizures; rufinamide; epileptic encephalopathies-childhoodYoung AdultRefractoryepileptic encephalopathies-childhoodrefractory seizuresrufinamideMedicineHumansYoung adultAdverse effectChildPreschoolepileptic encephalopathies-childhoodBrain DiseasesEpilepsybusiness.industryEpileptic encephalopathies-childhood; Refractory seizures; RufinamideTriazolesmedicine.diseaseSettore MED/39 - Neuropsichiatria Infantilerefractory seizuresMigraineepileptic encephalopathies-childhood refractory seizures rufinamideNeurologyAnesthesiaChild PreschoolVomitingAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessEpileptic encephalopathies-childhood; Refractory seizures; Rufinamide; Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child Preschool; Epilepsy; Female; Humans; Male; Triazoles; Young Adult; Neurology (clinical); NeurologyLennox–Gastaut syndromemedicine.drug
researchProduct

Critical limb ischaemia: definition and natural hystory

2004

The term critical limb ischemia refers to a condition characterized by chronic ischemic at-rest pain, ulcers, or gangrene in one or both legs attributable to objectively proven arterial occlusive disease. Critical limb ischemia implies chronicity and is to be distinguished from acute limb ischemia. Its incidence is approximately 500 to 1000 per million year, with the highest rates among older subjects, smokers and diabetics. The rate of primary amputation ranges from 10% to 40%, and was performed only when no graftable distal vessels were present, or in neurologically impaired or hopelessly nonambulatory patients. Contrarily, in some highly specialized and aggressive centres about 90% of pa…

critical limb ischemiamedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentRevascularizationAmputation SurgicalGangrenearterial occlusive diseaseIschemiaRisk Factorscardiovascular mortalityInternal medicinePeripheral arterial diseaseMedicineHumansMyocardial infarctionStrokePharmacologyGangrenePeripheral Vascular DiseasesLegbusiness.industryFootcardiovascular morbiditysurgical revascularizationHematologyCritical limb ischemiamedicine.diseaseIntermittent claudicationFontaine’s classificationSurgerybody regionsNatural historyAmputationrisk factors amputationCardiologyMolecular Medicinemedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct